Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug

• Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors

  New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
  
  MarketWatch - 37m
• 

  Weight Loss Drug Will Be Offered for $499 a Month for Some Patients

  Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.
  
  The New York Times - 4d
• 

  'Size bias is ingrained in our culture': Women on life after weight-loss jabs

  Women who have quickly lost weight say strangers are now more likely to smile at them or strike up a conversation.
  
  BBC News - 1d

• Pep after loss: City's UCL spot won't fall from sky

  Pep Guardiola has warned his Manchester City players that they have to earn a place in the Champions League and that it won't "come from the sky."
  
  ESPN - 1d
• 

  Legacy of weight-loss pioneer remembered

  Margaret Miles-Bramwell's colleagues remember her life and legacy ahead of her funeral on Monday.
  
  BBC News - 1d
• 

  Google's Latest Pixel Update Lets You Generate Images of People

  Plus: Dell debuts affordable QD-OLED gaming monitors, Polaroid upgrades its instant cameras, and Circular has a new smart ring.
  
  Wired - 2d
• 

  'You lose all hope': Federal workers gripped by mental health distress amid Trump cuts

  In interviews with NBC News, many federal workers shared stories of overwhelming stress, personal crises, rapid weight loss, panic attacks and more.
  
  NBC News - 1d
• 

  Fired Federal Workers See Family Members Pile on After the DOGE Axe Falls

  The abrupt loss of their livelihoods was tough enough. Now many laid-off government workers report their relatives and friends are celebrating their turmoil.
  
  Inc. - 2d
• 

  Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly

  Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance
  
  ABC News - 4d

More from CNBC

• Trump rejects pleas from business for more clarity on tariffs: 'They always say that'

  Trump and his aides warned amid the tariff controversy that Americans could be in store for some temporary economic strain — including higher prices.
  
  CNBC - 39m

• Here's why banks don’t want the CFPB to disappear

  The Consumer Financial Protection Bureau and its employees are in limbo after acting Director Russell Vought took over last month.
  
  CNBC - 1h

• Energy Secretary Chris Wright vows to reverse Biden climate policies, says renewables can't replace natural gas

  "The Trump administration will end the Biden administration's irrational, quasi-religious policies," Wright said at the CERAWeek by S&P Global energy conference.
  
  CNBC - 5m

• Kugler says Fed should hold interest rates amid inflation risks

  Inflation could continue to be 'persistent' and prices could potentially increase again, Federal Reserve Governor Adriana Kugler told CNBC's Silvia Amaro.
  
  CNBC - 1h

• Volkswagen and Stellantis evade Trump's 25% tariffs, while BMW braces for impact

  Some European car manufacturers may be able to avoid new U.S. tariffs, at least temporarily.
  
  CNBC - 40m

More in Business

• Energy Secretary Chris Wright vows to reverse Biden climate policies, says renewables can't replace natural gas

  "The Trump administration will end the Biden administration's irrational, quasi-religious policies," Wright said at the CERAWeek by S&P Global energy conference.
  
  CNBC - 5m

• Redfin’s stock soars on buyout deal by Rocket Cos that looks to speed up home buying

  Rocket wants to be a one-stop shop for the entire home-buying process.
  
  MarketWatch - 11m

• Do older adults understand healthcare risks?

  Misperceptions of long-term care needs and costs are cause for concern
  
  MarketWatch - 18m
• 

  Stocks Drop as Recession Fears Surface

  Investors fear that tit-for-tat tariffs could raise prices, slow growth and sow uncertainty among businesses.
  
  The New York Times - 22m

• These 13 growth stocks have dropped this year. They are expected to roar back.

  These companies are expected by analysts to increase revenue by at least double the rate of the S&P 500. Their stocks are expected to rise at least 29% over the next 12 months.
  
  MarketWatch - 24m